Skip to main content
. 2026 Oct 14;3(1):e20260040. doi: 10.70962/jhi.20260040

Figure 10.

Table showing individual responses to leniolisib treatment. The columns are labeled with Patient ID, Percent change from baseline for Index lymph nodes, Spleen, and Naive B cells, IRT use, Start of OLE, and Latest time point. The rows are labeled with individual patient IDs. Each cell contains specific data points for percent change from baseline, IRT use, start of OLE, and latest time point. The table includes color-coded cells to indicate different ranges of percent change and IRT use status. Notable trends include variations in percent change from baseline across different patients and time points.

Individual response to leniolisib treatment. Slashed line indicates data were not available to determine percent change from baseline. ID, identification; P, patient; RCT, randomized placebo-controlled trial. *No imaging was completed in DFT or RCT. †OLE baseline was defined as the start of either the DFT or RCT. For naïve B cells, if a patient had a treatment gap >42 days between the DFT or RCT and the OLE, or they did not participate in either trial, ED 1 values were used as baseline. ‡No imaging completed in OLE. §Spleen volume normalized (<314.5 cm3) by OLE assessment in a patient with splenomegaly at baseline. ||Normal spleen volume (<314.5 cm3) at baseline and at OLE assessment. ¶ED 1 was used as baseline for this patient as they had a >42-day gap between studies, but the patient continued to receive leniolisib between the studies. Naïve B cells at this time point were high (92.5%).